Disease Markers

Research Article

Identification of CCL20 and LCN2 as Efficient Serological Tools for Detection of Hepatocellular Carcinoma

Table 1

Baseline characteristics of subjects.


	Healthy ()	LC ()	HCC ()	Sig^a

Gender (, %)	51.9	52.8	58.7
Age ()
Stage (%)		Compensated: 64.15	BCLC 0: 5.39
		Decompensated: 35.85	BCLC A: 16.17
			BCLC B: 28.14
			BCLC C: 38.32
			BCLC D: 11.98
HBsAg (positive, %)		90.6	89.8	n.s.
AFP^b (ng/ml)	3.75 (2.09-5.88)	7.81 (3.69-19.74)	9.27 (5.42-31.13)
CA199^b (ng/ml)	16.36 (9.38-23.54)	18.71 (5.79-41.57)	19.85 (8.36-39.63) ^c

^aComparison between 3 groups. ^bData were presented as median with quartile (Q1-Q3). ^cNot significant vs. LC. LC: liver cirrhosis; HCC: hepatocellular carcinoma; n.s.: not significant. .